830 related articles for article (PubMed ID: 31715131)
1. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
Grosser R; Cherkassky L; Chintala N; Adusumilli PS
Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
Front Immunol; 2018; 9():2204. PubMed ID: 30319648
[TBL] [Abstract][Full Text] [Related]
3. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
Front Immunol; 2020; 11():1109. PubMed ID: 32625204
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
Zhang F; Stephan SB; Ene CI; Smith TT; Holland EC; Stephan MT
Cancer Res; 2018 Jul; 78(13):3718-3730. PubMed ID: 29760047
[TBL] [Abstract][Full Text] [Related]
5. Immune resilience in response to cancer therapy.
Gicobi JK; Barham W; Dong H
Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
[No Abstract] [Full Text] [Related]
6. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Yoon DH; Osborn MJ; Tolar J; Kim CJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
[TBL] [Abstract][Full Text] [Related]
7. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
Leone RD; Powell JD
Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
[TBL] [Abstract][Full Text] [Related]
8. Development of adaptive immune effector therapies in solid tumors.
Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
10. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB
Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903
[TBL] [Abstract][Full Text] [Related]
11. The Reciprocity between Radiotherapy and Cancer Immunotherapy.
Wang Y; Liu ZG; Yuan H; Deng W; Li J; Huang Y; Kim BYS; Story MD; Jiang W
Clin Cancer Res; 2019 Mar; 25(6):1709-1717. PubMed ID: 30413527
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
13. CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.
Sacchetti B; Botticelli A; Pierelli L; Nuti M; Alimandi M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999624
[TBL] [Abstract][Full Text] [Related]
14. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
18. Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.
Bansal R; Reshef R
Blood Rev; 2021 Jan; 45():100695. PubMed ID: 32402724
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
20. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
